Description
Pradaxa (Dabigatran Etexilate) Capsules 150 mg. №60
Ingredients:
- Each capsule contains 150 mg of dabigatran etexilate.
Dosage:
- The recommended dose is one 150 mg capsule taken orally twice daily.
Indications:
- Pradaxa is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Contraindications:
- Do not use Pradaxa in patients with artificial heart valves or those with a history of hypersensitivity to dabigatran.
Directions:
- Swallow the capsule whole with a full glass of water. Do not crush or chew the capsule.
Scientific Evidence:
- Dabigatran etexilate, the active ingredient in Pradaxa, is a direct thrombin inhibitor that has shown non-inferiority to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation. The RE-LY trial demonstrated that dabigatran was as effective as warfarin in reducing the risk of stroke and had a lower risk of intracranial bleeding.
Additional Information:
- Pradaxa does not require routine monitoring of coagulation levels like warfarin, offering a more convenient option for patients. However, there is an increased risk of gastrointestinal bleeding associated with Pradaxa use.
- Extensive clinical trials have consistently shown the efficacy and safety profile of Pradaxa. Patients should consult their healthcare provider before starting Pradaxa to ensure suitability for their medical condition.
